The Ionizable Lipid Platform
for Next-Generation Delivery
Accelerating the pipelines of global pharma.
Empowering the service portfolio of global CDMOs.
Lipid Performance: Bio-similar and bio-superior lipids.
Intellectual Property: Solid multi-layered IP portfolio.
Optimization: Rapid lipid optimization cycles.
Performance Tuning: Tunable structural moieties.
Do you need more information?
Best-in-Class Platform
Multi-Layered IP
Covering the entire lipid value chain. Lipid structure space, lipid building blocks, lipid synthesis, lipids, lipid application.
Do you need more information?
Innovative chemical reaction with IP protected catalyst technology…
…creates proprietary silicon motifs
from standard chemicals…
…which are integrated into
novel ionizable lipids…
…forming unique LNPs for delivery of therapeutic payloads.
Composition of Matter Patents
Protecting catalysts necessary for lipid synthesis.
Composition of Matter Patents
Protecting lipid building blocks, lipids and the lipid structure space.
Use Patents
Protecting the application of lipids for TA specific delivery.
Best-in-Class Platform
Superior Transfection Efficacy
Superior transfection efficacy de-risks therapeutic development. AldexBIO lipids are superior to industry benchmarks, enabling lower doses with reduced safety concerns.
Do you need more information?
Best-in-Class Platform
Rapid Lipid Optimization
Off-the-shelf lipids performed for therapies of the past. De-risking the projects of today and tomorrow requires lipids optimized for specific challenges. Our rapid optimization platform delivers.
Do you need more information?
De-Risking Delivery
Excellent Safety
Our technology consistently outperforms industry benchmarks with significantly lower toxicity in both in vitro and preliminary in vivo studies and shows no adverse safety signals in functional testing.
Do you need more information?
HepG2 cell viability assay
180 of 240 lipids tested
77 less toxic than Industry Standards.
Human T-cell viability assay
35 of 240 lipids tested
9 comparable to Industry Standards.
Impact on cytokine levels in mice
5 of 240 lipids tested
no critical or “no go” observations.
In vivo transfection studies
47 lipids in 126 LNPs tested
no mortality, no loss of bodyweight,
no clinical observations.
Toxicity testing of LNPs in mice
5 of 240 lipids tested
no critical or “no go” observations.
Exploratory toxicity study in mice
3-4 lipids, 5 animals per group
Superior to industry benchmarks
De-Risking Delivery
Competition-Free Structure Space
Thousands of patents clutter the conventional lipid space, presenting serios litigation risks. Silicon makes the difference. Our novel silicon-based lipids occupy an uncontested lipid space without IP risks.
Do you need more information?
IP
Carbon-Only
Lipid Space
IP
Silicon
Lipid Space
AldexBIO
Contesting
IP
De-Risking Delivery
Self-Empowering Platform
AldexBIO employs a building-block approach to design and synthesize novel lipids. We constantly add new building blocks to our proprietary library, increasing synthetic speed for next gen lipids.
Do you need more information?
De-Risking Delivery
Structural Diversity
AldexBIO generates high structural diversity by freely combining a wide array of starting materials with our 24 proprietary silicon motifs. This unlocks lipid structures with highly optimized properties.
Do you need more information?
